Sequential Alteration of Apoptosis, p53 Expression, and Cell Proliferation in the Rat Pancreas Treated with 4-Hydroxyaminoquinoline 1-Oxide

Toxicologic Pathology

Volumn 31, Issue 6, 2003, Pages 625-631

  Imazawa, Takayoshi ^a   Nishikawa, Akiyoshi ^b   Toyoda, Kazuhiro ^b   Furukawa, Fumio ^b   Mitsui, Masayuki ^a   Hirose, Masao ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b JAPAN TOBACCO INC   (Japan)

Author keywords

4 hydroxyaminoquinoline 1 oxide; apoptosis; cell proliferation; p53 protein; pancreas; rat

Indexed keywords

4 HYDROXYAMINOQUINOLINE 1 OXIDE; CYCLINE; KI 67 ANTIGEN; PROTEIN P53;

ACINAR CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CARCINOGENESIS; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ELECTRON MICROSCOPY; EUTHANASIA; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INJECTION; ISOLATED LIVER; ISOLATED PANCREAS ISLET; LIVER CELL; MALE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STATISTICAL SIGNIFICANCE;

4-HYDROXYAMINOQUINOLINE-1-OXIDE; ANIMALS; APOPTOSIS; CARCINOGENS; CELL DIVISION; CELL NUCLEUS; IMMUNOENZYME TECHNIQUES; IN SITU NICK-END LABELING; INJECTIONS, INTRAVENOUS; KI-67 ANTIGEN; MALE; PANCREAS; PROLIFERATING CELL NUCLEAR ANTIGEN; RATS; RATS, SPRAGUE-DAWLEY; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA;

EID: 0242637142     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1080/01926230390241855     Document Type: Article

References (41)

1. Anderson CW (1993). DNA damage and DNA-activated protein kinase. TIBS 18: 433-437.
2. Baas IO, Muldér JR, Offerhaus JA, Vogelstein B., Hamilton SR (1994). An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172: 5-12.
3. Coats P., Save V., Ansari B., Hall PA (1995). Demonstration of DNA damage/repair in individual cells using in situ end labelling: association of p53 with site of DNA damage. J Pathol 176: 19-26.
4. Donehower LA, Bradley A. (1993). The tumor suppressor p53. Biochem Biophys Acta 1155: 181-205.
5. Doolittle DJ, McKarns SC, Ayres PH, Bombick DW (1992). Molecular approaches for quantifying DNA synthesis and cell proliferation during rodent bioassays. Toxicol Meth 1: 215-230.
6. Galiègue-Zouitina S., Bailleul B., Loucheux-Lefebvre MH (1985). Adducts from in vivo action of the carcinogen 4-hydroxyaminoquinoline 1-oxide in rats and from in vitro reaction of 4-acetoxyaminoquinoline 1-oxide with DNA and polynucleotides. Cancer Res 45: 520-525.
7. Gavrieli Y., Sherman Y., Ben-Sasson SA (1992). Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119: 493-501.
8. Gerdes J., Lemke H., Baisch H., Wacker HH, Schwab U., Stein H. (1984). Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133: 1710-1715.
9. Greenblatt MS, Bennet WP, Hollstein M., Harris CC (1994). Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878.
10. Hainaut P., Milner J. (1993). Redox of p53 conformation and sequencespecific DNA binding in vitro. Cancer Res 53: 4469-4473.
11. Hall PA, McKee PH, Merage HD, Dover R., Lane DP (1993). High levels of p53 protein in UV-irradiated normal human skin. Oncogene 8: 203-207.
12. Hall PA, Lane DP (1994). p53 in tumor pathology: can we trust immunohistochemistry revisited. J Pathol 172: 1-4.
13. Harris CC (1993). p53: at the crossroads of molecular carcinogenesis and risk assessment. Science 262: 1980-1981.
14. Hayashi Y., Hasegawa T. (1970). Nucleolar alterations of alveolar epithelial cells in rats following a single injection of 4-nitroquinoline 1-oxide. Gann 61: 347-352.
15. Hayashi, Y., Hasegawa T. (1971). Experimental pancreatic tumors in rats after intravenous injection of 4-hydroxyaminoquinoline 1-oxide. Gann 62: 329-330.
16. Hayashi Y., Furukawa H., Hasegawa T. (1972). Pancreatic tumors in rats induced by 4-nitroquinoline 1-oxide derivatives. In: Topics in Chemical Carcinogenesis, Nakahara W, Takayama S, Sugimura T, Odashima S (eds). University Park Press, Baltimore, pp 53-72.
17. Imazawa T., Nishikawa A., Shibutani M., Ogasawara H., Furukawa F., Ikeda T., Suda K., Hirose M. (2001). Induction of pancreatic islet cell tumors in rats by repeated intravenous administration of 4-hydroxyaminoquinoline 1-oxide. Toxicol Pathol 29: 320-327.
18. Imazawa T., Nishikawa A., Tada M., Takahashi M., Hayashi Y. (1995). Nucleolar segregation as an early marker for DNA damage; an experimental study in rats treated with 4-hydroxyaminoquinoline 1-oxide. Virchows Arch 426: 295-300.
19. Kastan MB, Onyerkwere O., Sidransky D., Vogelstein B., Craig RW (1991). Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311.
20. Kelman Z. (1997). PCNA: structure, functions and interactions. Oncogene 14: 629-640.
21. Kemp CJ (1995). Hepatocarcinogenesis in p53-defiecient mice. Mol Carcinogen 12: 132-136.
22. Kisilevsky R. (1974). Hepatic nuclear and nucleolar changes in amanita poisoning. Arch Pathol 97: 253-258.
23. Konishi Y., Maruyama H., Mii Y., Miyauchi Y., Yokose Y Masuhara K. (1982). Malignant fibrous histocytomas induced by 4-hydroxyaminoquinoline 1-oxide in rats. J Natl Cancer Inst 68: 859-865.
24. Lane DP, Benchimol S. (1990). p53: oncogene or anti-oncogene. Genes Dev 4: 1-8.
25. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. (1993). p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847-849.
26. Miller EC (1978). Some current perspectives on chemical carcinogensis in humans and experimental animals: Presidential address. Cancer Res 38: 1479-1496.
27. Milne DM, Campbell DG, Caudwell FB, Meek W. (1994). Phosphorylation of the tumor supressor protein p53 by mitogen-activated protein kinases. J Biol Chem 269: 9253-9260.
28. Mori K., Ohta A., Murakami T., Tamura M., Kondo M., Ichimura H. (1969). Carcinomas of the glandular stomach and other organs of rats by 4-hydroxyaminoquinoline 1-oxide hydrochloride. Gann 60: 627-630.
29. Mosner J., Deppert W (1994). p53 and mdm2 are expressed independently during cellular proliferation. Oncogene 9: 3321-3328.
30. Nakagawa K., Tada M., Morita T., Utsunomiya J., Ishikawa T. (1988). Immunohistochemical detection of 4-hydroxyaminoquinoline 1-oxide-DNA adducts in mouse tissues in vivo. J Natl Cancer Inst 80: 419-425.
31. Poirier MC (1981). Antibodies to carcinogen-DNA adducts. J Natl Cancer Inst 67: 515-519.
32. Raff MC (1992). Social controls on cell survival and cell death. Nature 356: 398-400.
33. Rao MS, Upton MP, Subbarao V., Scarpelli DG (1982). Two populations of cells with differing proliferative capacities in atypical acinar cell foci induced by 4-hydroxyaminoquinoline 1-oxide in the rat pancreas. Lab Invest 46: 527-534.
34. Shi SR, Key ME, Kalra KL (1991). Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method forimmunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39: 741-748.
35. Shivakumar CV, Brown DR, Deb S., Deb SP (1995). Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter. Mol Cell Biol 15: 6785-6793.
36. Sugimura T. (1981). The nitroquinolines. In: Carcinogenesis, Sugimura T (ed). Raven Press, New York, Vol 6, pp 1-153.
37. Tada M., Kohda KH, Kawazoe Y. (1984). Biomimetic preparation and structure determination of QGI, one of the quinoline-DNA base adducts formed in cells treated with 4-nitroquinoline 1-oxide. Gann 75: 976-985.
38. Toschi L., Bravo R. (1988). Changes in cyclin/proliferating cell nuclear antigen distribution during DNA repair synthesis. J Cell Biol 107: 1623-1628.
39. van Dierendonck JH, Wijsman JH, Keijzer R., van de Velde Cjh, Cornelisse CJ (1991). Cell-cycle-related staining patterns of anti-proliferating cell nuclear antigen monoclonal antibodies. Am J Pathol 138: 1165-1172.
40. Williams GT (1991). Programmed cell death: apoptosis and oncogenesis. Cell 65: 1097-1098.
41. Yonishi-Rouach E. (1991). Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352: 345-347.